Skip to main content

Table 1 Baseline characteristics of study groups

From: Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials

 

BMI <25 kg/m2

BMI 25–<30 kg/m2

BMI 30–<35 kg/m2

BMI ≥35 kg/m2

P value

Total patient count, n (%)

133 (20 %)

222 (34 %)

166 (25 %)

141 (21 %)

 

Age (years), mean (SD)

57.2 (10.4)

58.0 (9.5)

57.3 (9.7)

56.5 (9.8)

0.58*

Gender

0.0495**

 Female, n (%)

62 (46.6)

117 (52.7)

88 (53.0)

89 (63.1)

 

 Male, n (%)

71 (53.4)

105 (47.3)

78 (47.0)

52 (36.9)

 

Baseline weight (kg), mean (SD)

61.0 (9.0)

73.8 (9.9)

88.9 (11.8)

110.4 (18.6)

<0.0001*

Baseline BMI (kg/m2), mean (SD)

23.1 (1.5)

27.6 (1.5)

32.4 (1.4)

40.3 (5.0)

<0.0001*

Diabetes duration (years), mean (SD)

13.1 (7.7)

12.4 (6.8)

11.3 (7.1)

10.4 (6.8)

0.0043*

OAD history (years), mean (SD)

5.9 (4.8)

6.4 (6.2)

6.7 (5.4)

5.6 (4.4)

0.29*

Insulin history (years), mean (SD)

2.3 (3.9)

2.2 (3.2)

1.7 (2.5)

1.9 (3.2)

0.35*

  1. BMI body mass index, SD standard deviation, OAD oral antidiabetic drug
  2. * Statistical significance of differences was determined by ANOVA
  3. ** Statistical significance of differences was determined by X2 test